Literature DB >> 21337878

Prognostic significance of tumor infiltrating lymphocytes in melanoma.

Alison L Burton1, Brent A Roach, Michael P Mays, Andrea F Chen, Brooke A R Ginter, Abbey M Vierling, Charles R Scoggins, Robert C G Martin, Arnold J Stromberg, Lee Hagendoorn, Kelly M McMasters.   

Abstract

The prognostic significance of tumor infiltrating lymphocyte (TIL) response in cutaneous melanoma is controversial. This analysis of data from a prospective, randomized trial included patients with cutaneous melanoma > or = 1.0 mm Breslow thickness who underwent wide local excision and sentinel lymph node (SLN) biopsy. Univariate and multivariate analyses were performed to determine factors associated with TIL response, disease-free survival (DFS), and overall survival (OS). A total of 515 patients were included; TIL response was classified as "brisk" (n = 100; 19.4%) or "non-brisk" (n = 415; 80.6%). Patients in the nonbrisk TIL group were more likely to have tumor-positive SLN (17.6% vs 7%; P = 0.0087). On multivariate analysis, nonbrisk TIL response, increased tumor thickness, and ulceration were significant independent predictors of tumor-positive SLN. By Kaplan-Meier analysis, 5-year DFS rate was 91 per cent for those with a brisk TIL response compared with 86 per cent in the nonbrisk group (P = 0.41). The 5-year OS rates were 95 per cent versus 84 per cent in the brisk versus nonbrisk TIL groups, respectively (P = 0.0083). However, on multivariate analysis, TIL response was not a significant independent factor predicting DFS or OS. TIL response is a significant predictor of SLN metastasis but is not a major predictor of DFS or OS.

Entities:  

Mesh:

Year:  2011        PMID: 21337878

Source DB:  PubMed          Journal:  Am Surg        ISSN: 0003-1348            Impact factor:   0.688


  28 in total

1.  Decreased VDR expression in cutaneous melanomas as marker of tumor progression: new data and analyses.

Authors:  Anna A Brożyna; Wojciech Jóźwicki; Andrzej T Slominski
Journal:  Anticancer Res       Date:  2014-06       Impact factor: 2.480

2.  Immunologic heterogeneity of tumor-infiltrating lymphocyte composition in primary melanoma.

Authors:  Sarah A Weiss; Sung Won Han; Kevin Lui; Jeremy Tchack; Richard Shapiro; Russell Berman; Judy Zhong; Michelle Krogsgaard; Iman Osman; Farbod Darvishian
Journal:  Hum Pathol       Date:  2016-07-26       Impact factor: 3.466

3.  Immune biomarkers are more accurate in prediction of survival in ulcerated than in non-ulcerated primary melanomas.

Authors:  Ellen H de Moll; Yichun Fu; Yingzhi Qian; Sara H Perkins; Shira Wieder; Sacha Gnjatic; Romain Remark; Sebastian G Bernardo; Marina Moskalenko; Jonathan Yao; Tammie Ferringer; Rui Chang; Jerry Chipuk; Basil A Horst; Miriam B Birge; Robert G Phelps; Yvonne M Saenger
Journal:  Cancer Immunol Immunother       Date:  2015-06-16       Impact factor: 6.968

4.  Increased number of forkhead box P3+ tumor-infiltrating lymphocytes correlates with high preoperative albumin level and better survival in patients with stage II or III colorectal cancer.

Authors:  Dong-liang Wang; Yan-yan Liu; Yuan-long Gu; Yu Qin; Hong-fei Ji; Li-hua Wu; Ning Qi; Dan Su; Sun-hui Huang; Yan-qiao Zhang
Journal:  Tumour Biol       Date:  2015-02-20

5.  Molecular profiling reveals low- and high-grade forms of primary melanoma.

Authors:  Katja Harbst; Johan Staaf; Martin Lauss; Anna Karlsson; Anna Måsbäck; Iva Johansson; Pär-Ola Bendahl; Johan Vallon-Christersson; Therese Törngren; Henrik Ekedahl; Jürgen Geisler; Mattias Höglund; Markus Höglund; Markus Ringnér; Mattias Ringnér; Lotta Lundgren; Karin Jirström; Håkan Olsson; Christian Ingvar; Åke Borg; Hensin Tsao; Göran Jönsson
Journal:  Clin Cancer Res       Date:  2012-06-06       Impact factor: 12.531

Review 6.  Revisiting determinants of prognosis in cutaneous melanoma.

Authors:  Sarah A Weiss; Douglas Hanniford; Eva Hernando; Iman Osman
Journal:  Cancer       Date:  2015-08-26       Impact factor: 6.860

Review 7.  Emerging Biomarkers in Cutaneous Melanoma.

Authors:  Anna Eisenstein; Estela Chen Gonzalez; Rekha Raghunathan; Xixi Xu; Muzhou Wu; Emily O McLean; Jean McGee; Byungwoo Ryu; Rhoda M Alani
Journal:  Mol Diagn Ther       Date:  2018-04       Impact factor: 4.074

8.  Tumor infiltrating lymphocytes in acral lentiginous melanoma: a study of a large cohort of cases from Latin America.

Authors:  C A Castaneda; C Torres-Cabala; M Castillo; V Villegas; S Casavilca; L Cano; J Sanchez; J Dunstan; G Calderon; M De La Cruz; J M Cotrina; H L Gomez; R Galvez; J Abugattas
Journal:  Clin Transl Oncol       Date:  2017-06-02       Impact factor: 3.405

9.  Molecular analysis of primary melanoma T cells identifies patients at risk for metastatic recurrence.

Authors:  Wiebke Pruessmann; Julie Rytlewski; James Wilmott; Richard A Scolyer; Thomas S Kupper; Martin C Mihm; Grace H Attrill; Beatrice Dyring-Andersen; Paul Fields; Qian Zhan; Andrew J Colebatch; Peter M Ferguson; John F Thompson; Klaus Kallenbach; Erik Yusko; Rachael A Clark; Harlan Robins
Journal:  Nat Cancer       Date:  2020-01-20

10.  Is There a Relationship Between TILs and Regression in Melanoma?

Authors:  Steven Morrison; Gang Han; Faith Elenwa; John T Vetto; Graham Fowler; Stanley P Leong; Mohammed Kashani-Sabet; Barbara Pockaj; Heidi E Kosiorek; Jonathan S Zager; Jane L Messina; Nicola Mozzillo; Schlomo Schneebaum; Dale Han
Journal:  Ann Surg Oncol       Date:  2022-01-21       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.